Correspondence 0001213900-23-081748 from Ping An Biomedical Co., Ltd. (PASW)
Ping An Biomedical Co., Ltd.
Date: Oct. 31, 2023 · CIK: 0001897532 · Accession: 0001213900-23-081748
AI Filing Summary & Sentiment
File numbers found in text: 333-271502
Referenced dates: October 26, 2023
Show Raw Text
CORRESP
1
filename1.htm
October 31, 2023
Via Edgar Transmission
Mr. Thomas Jones
Securities and Exchange Commission
Division of Corporation Finance
Office of Trade & Services
Washington, D.C. 20549
Re:
Majestic Ideal Holdings Ltd
Amendment No. 3 to Registration Statement on Form
F-1
Filed October 20, 2023
File No. 333-271502
Dear Mr. Jones:
As counsel for the Company
and on its behalf, this letter is being submitted in response to the letter dated October 26, 2023 from the Securities and Exchange Commission
(the “Commission”) in which the staff of the Commission (the “Staff”) commented on the above-referenced
Registration Statement on Form F-1 (the “Form F-1”).
For the Staff’s convenience,
the Staff’s comment has been stated below in its entirety, with the Company’s response set out immediately underneath such
comment.
Amendment No. 3 to Registration Statement on
Form F-1 filed October 20, 2023
General
1. We note your response to prior comment 1 and we reissue the comment. Please amend to provide the information summarized
and requested in the prior comment.
Response: We respectfully
advise the Staff that we have updated the disclosure appearing on the cover page, Summary and Risk Factor sections to restore relevant
risk disclosures in relation to legal and operational risks associated with operating in China and PRC regulations.
Dilution, page 44
2. Your revised disclosures in response to prior comment 2 indicate that your intangible assets include
deferred IPO costs, right-of-use assets and deferred tax assets and are therefore excluded from net tangible book value. It appears as
though your net tangible book value as currently presented does not exclude your right-of-use assets of RMB712,011. Please revise.
Response: We respectfully
advise the Staff that we have revised the disclosures on page 44
3. In a related matter, your current presentation lists your net tangible book value in USD with the $,
however, your calculated value is actually from your March 31, 2023 balance sheet in RMB. In addition, your net tangible book value per
share is presented according to the USD figures. Please revise to present your net tangible book value in U.S. Dollars to align with your
net tangible book value per share.
Response: We respectfully
advise the Staff that we have revised the disclosures on page 44
Compensation of Directors and Executive Officers,
page 93
4. Please update the disclosure in this section to include compensation information for the most recently
completed fiscal year.
Response: We
respectfully advise the Staff that we have updated the compensation disclosure on page 93 for the fiscal year ended September 30,
2023.
Financial Statements, page F-1
5. We note this registration statement is your initial public offering. In this regard, your audited financial
statements must be no more than 12 months old at the time of filing and upon the effectiveness of the registration statement unless you
are able to represent the you are not required to comply with the 12 month requirement in any other jurisdiction outside the United States
and that complying with the 12 month requirement is impracticable or involves undue hardship in which case the last year of audited financial
statements may not be older than 15 months at the time of offering. If applicable, your representation should be filed as an exhibit to
the registration statements. Refer to the Instructions to Item 8.A.4 of Form 20-F.
Response: We respectfully advise
the Staff that we have included with the registration statement a request for waiver filed as exhibit 99.6.
* * *
Please contact the undersigned
at (852) 3923-1188 if you have any questions with respect to the responses contained in this letter.
Sincerely,
/s/ Lawrence S. Venick
Lawrence S. Venick
Direct Dial: +852.3923.1188
Email: lvenick@loeb.com